Create Account | Sign In: Author or Forum

 
 
News  |  Journals  |  Conferences  |  Blogs  |  Articles  |  Forums  |  Twitter    
 

 Headlines:

 

Category: Endocrinology | Family Medicine | Geriatrics | Internal Medicine | Nursing | Oncology | Pharmacy | Journal

Back to Journal Articles

Survival Reduced for Patients With Cancer Who Have Diabetes

Last Updated: January 26, 2012.

 

Type of cancer and diabetes treatment influence survival

Share |

Comments: (0)

Tell-a-Friend

 

  Related
 
Patients with cancer generally have reduced survival if they also have type 2 diabetes, although this depends on the type of cancer and diabetes treatment, according to a study published online Jan. 20 in Diabetes Care.

THURSDAY, Jan. 26 (HealthDay News) -- Patients with cancer generally have reduced survival if they also have type 2 diabetes, although this depends on the type of cancer and diabetes treatment, according to a study published online Jan. 20 in Diabetes Care.

Craig J. Currie, Ph.D., from Cardiff University in the United Kingdom, and colleagues examined survival in 112,408 patients newly diagnosed with cancer, of whom 7.5 percent also had type 2 diabetes.

The researchers found that diabetes was associated with overall higher cancer mortality (hazard ratio [HR], 1.09) but depended on the type of cancer, with greater mortality in patients with breast (HR, 1.32) and prostate (HR, 1.19) cancer but a lower mortality in patients with lung cancer (HR, 0.84). Compared with patients who did not have diabetes, mortality was higher in patients with diabetes treated with sulfonylureas or insulin alone (HR, 1.13 for each) but lower in patients treated with metformin alone (HR, 0.85).

"This study confirmed that type 2 diabetes was associated with poorer prognosis after incident cancer, but that the association varied according to diabetes therapy and cancer site," Currie and colleagues write. "Metformin was associated with survival benefit both in comparison with other treatments for diabetes and in comparison with a nondiabetic population."

Several authors disclosed financial relationships with pharmaceutical or biotechnology companies.

Abstract
Full Text (subscription or payment may be required)

Copyright © 2012 HealthDay. All rights reserved.


Previous: Mutations in IDH1/2 Seen in Intrahepatic Bile Duct Cancers Next: Exposure to Iodinated Contrast Media Affects Thyroid Function

Reader comments on this article are listed below. Review our comments policy.


Submit your opinion:

Name:

Email:

Location:

URL:

Remember my personal information

Notify me of follow-up comments?

advertisement.gif (61x7 -- 0 bytes)
 

Are you a Doctor, Pharmacist, PA or a Nurse?

Join the Doctors Lounge online medical community

  • Editorial activities: Publish, peer review, edit online articles.

  • Ask a Doctor Teams: Respond to patient questions and discuss challenging presentations with other members.

Doctors Lounge Membership Application

 
     

 advertisement.gif (61x7 -- 0 bytes)

 

 

Useful Sites
MediLexicon
  Tools & Services: Follow DoctorsLounge on Twitter Follow us on Twitter | RSS News | Newsletter | Contact us
Copyright © 2001-2014
Doctors Lounge.
All rights reserved.

Medical Reference:
Diseases | Symptoms
Drugs | Labs | Procedures
Software | Tutorials

Advertising
Links | Humor
Forum Archive
CME | Conferences

Privacy Statement
Terms & Conditions
Editorial Board
About us | Email

This website is certified by Health On the Net Foundation. Click to verify. This site complies with the HONcode standard for trustworthy health information:
verify here.